Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience

Table 2 Clinical outcomes

Patient No.	Before administering of RTX (0 mo)			After administering of RTX (6 mo)				Follow-up (12 mo)
	24 h UTP (g/d)	ALB (g/L)	Scr (μmol/L)	24 h UTP (g/d)	ALB (g/L)	Scr (μmol/L)	Remission	24 h UTP (g/d)	ALB (g/L)	Scr (μmol/L)	Remission
1	15.2	13.9	97	2.3	25.1	64	PR	1.88	44	66	PR
2	7.1	29	78	3.6	36.9	72	NR	2	36.2	83	PR
3	17	16	202	9.9	24.3	93	NR	4	29.9	116	PR
4	6.7	26	142	-	-	-	-	-	-	-	-
5	5.7	35	84	1.03	45.1	64	PR	0.09	49.5	90	CR
6	1.8	37.4	78	1.3	42	82	PR	0.6	40.1	75	PR
7	3.5	32.5	90	1.8	35.1	69	PR	0.27	44.1	88	CR
8	15	26.9	91	6.2	29.4	70	PR	0.9	41.4	82	PR
9	1.3	35.8	125	0.64	39.1	111	PR	0.175	42.2	124	CR

UTP: Urinary protein quantitation; RTX: Rituximab; ALB: Albumin; Scr: Serum creatinine; PR: Partial remission; CR: Complete remission; NR: No remission.